Europe To Drive Global R&D Collaborations With Pharma Companies
Executive Summary
Alzheimer’s disease research could be a beneficiary of Europe’s plan to include more non-EU partners in its new science funding program, Horizon 2020, and a new version of its public-private partnership with the pharmaceutical industry, the Innovative Medicines Initiative.
You may also be interested in...
Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed
Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”
EU’s IMI, Drug Makers And Universities Join In New R&D Effort
Europe’s latest push to speed up new medicine discovery will see a new European Lead Factory set up under the EU’s Innovative Medicines Initiative, combining a library of up to 500,000 drug candidates from industry and academia and high-throughput screening centers to identify and generate new therapies.
Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.